Skip navigation
>»
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

Novel Therapies meetings & conferences

9 meetings & conferences listed in Novel Therapies 

4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community
United States
California
02/05/2015

4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community

February 5-7, 2015 Santa Clara, California

The 4th Santa Clara Valley Brain Injury Conference: Building on the Legacy of Coma to Community, will be held February 5-7, 2015 at the Marriott Santa Clara, 2700 Mission Boulevard, Santa Clara, CA 95054.

This conference is the updated continuation of the Coma to Community Conference hosted by Santa Clara Valley Medical Center from 1977 through 1995.  We anticipate an audience of 500 rehabilitation professionals representing a variety of disciplines as well as individuals with brain injury, family members, and caregivers.  Our previous conferences were endorsed by the American Congress of Rehabilitation Medicine and the Brain Injury Association of America, and the International Brain Injury Association.

The main conference includes two days of multi-disciplinary state of the art educational sessions focusing on issues related to acquired brain injury treatment and research in both a military and civilian population.  The 2015 conference will feature multiple half-day pre-conference workshops as an optional add-on.

The 2015 main conference will focus on:

1. Medical Complexity and Acute and Chronic Treatment (successful strategies and new approaches)

2. Innovative Interventions and Assistive Devices (new technology, stem cells and others)

3. Living After Brain Injury (socialization, relationships, advocacy and caregiving)

4. Special Populations (military and veteran issues, cultural competence, dual diagnosis, pediatrics, and aging

The conference curriculum will appeal to social workers, therapists, psychologists, physiatrists, nurses, researchers, administrators, advocates, individuals with brain injury and family members affected by brain injury.  Presentation formats will include lectures, panel discussions, and interactive workshops.  Peer reviewed symposia and poster presentations will be an integral part of the program allowing for the sharing of information regarding research and innovative multidisciplinary treatment approaches.  We will be offering CME's for the main conference and CME's for the pre-conferences for a variety of disciplines.

In addition to faculty, comprised of nationally and internationally recognized leaders in the field of brain injury and rehabilitation, there will be exhibitors sharing the latest innovations and information regarding services for individuals with brain injury and their families.

Family Caregiver, Neurologist, Neuroscientist, Nurse, Nurse Researcher, Pediatric Nurse, Pediatrician, Physiatrist, Physical Therapist, Physician, Physician Researcher, Social Worker
8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015)
France
02/18/2015

8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015)

February 18-21, 2015 Paris, France

The 8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2015) follows the success of previous meetings including ATTD 2014 which attracted 2,084 participants from 80 countries, where all participants agreed that this is the main networking event in the field!

ATTD 2015 will attract an international audience of researchers and clinicians from the fields of diabetes, endocrinology and metabolism, diabetes technology developers as well as general & family medicine practitioners.

Join us for ATTD 2015 in the beautiful city of light, Paris, France, on February 18-21, 2015 for this conference which focuses on a unique niche and offers unparalleled networking opportunities.

Biomedical Engineer, Endocrinologist, Family Physician, Informatician, Internist, Physician, Physician Researcher, Technologist
3rd International Conference on Immune Tolerance 2014
Netherlands
09/28/2014

3rd International Conference on Immune Tolerance 2014

28th - 30th September 2014 Amsterdam, the Netherlands

Interest in the immune tolerance field continues to grow. Following the successful second International Conference, held in Amsterdam in October 2011, the Third International Conference on Immune Tolerance will bring together international delegates to share their latest research and insights into the mechanisms and treatment of many conditions, most notably in transplantation, autoimmune diseases, inflammation and cancer. This Conference is supported by the established journal Cellular Immunology, which publishes rapidly high-quality, peer-reviewed papers in this exciting field.

Topic List

• Immune homeostasis: immunity versus tolerance

• Tumor

• Central nervous system-targeted autoimmunity

• Tissue-specific autoimmunity: interplay of immune effector and tissue resident cells

• B cell differentiation pathways and disease susceptibility

• Transplant rejection and engraftment

• Next generation immune-based therapies

Immunologist, Oncologist, Physician Researcher
Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach
United States
New York
10/28/2014

Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

Tuesday, October 28, 2014  8:30 AM - 5:00 PM The New York Academy of Sciences

Presented by the Biochemical Pharmacology Discussion Group

Uncontrolled, chronic inflammation is now considered a major component of many widespread diseases, which are now well-recognized as 'inflammatory diseases.' These include arthritis, asthma, atherosclerosis and peripheral vascular disease, Alzheimer’s disease, periodontal disease and cancer. There is general agreement that inflammation is not likely to be the causative factor in these diseases, but that it plays a key role in disease progression, tissue dysfunction and ultimately organ failure. In recent years, evidence has emerged that resolution of inflammation is a biochemically active process driven by multiple chemical mediators. Elucidation of the biochemical pathways contributing to the resolution of inflammation has provided many new anti-inflammatory targets and an opportunity for resolution-based pharmacology for treatment and prevention of inflammatory diseases. This symposium reviews recent discoveries and advances in the field, and demonstrates how this work translates into new approaches and new pharmacology to treat old diseases.

Pharmacologist, Physician Researcher
Emerging Issues and New Frontiers for FDA Regulation
United States
Washington, DC
10/20/2014

Emerging Issues and New Frontiers for FDA Regulation

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Food and Drug Law Institute are pleased to announce an upcoming collaborative academic symposium:

Emerging Issues and New Frontiers for FDA Regulation Monday, October 20, 2014 Washington, DC

Lawyer, Physician Researcher, Policy Analyst, Public Health Expert, Public Health Worker, Public Servant
Eleventh International Kawasaki Disease Symposium
United States
Hawaii
02/03/2015

Eleventh International Kawasaki Disease Symposium

Feb. 3-6, 2015 Honolulu, Hawaii

This 3 ½ day conference includes lectures, discussions, and oral/poster presentations focusing on the latest advances in Kawasaki disease. Kawasaki disease is the major cause of acquired childhood heart disease in developed countries. Children who develop significant coronary artery aneurysms as a result of Kawasaki disease have a lifetime increased risk of myocardial ischemia, infarction, and sudden death. The study of Kawasaki disease and its treatment are likely to yield important answers to general questions in cardiovascular health and disease that apply equally to pediatric and adult populations.

The Eleventh International Kawasaki Disease Symposium seeks to address the influence of genetics on disease susceptibility and outcomes, the mechanisms of coronary artery damage following severe acute inflammation, the role of immune modulation and other novel therapies in preventing artery damage, the potential use of serum biomarkers for diagnosis and prognosis, the use of newer imaging techniques to assess abnormalities of the coronary arteries and myocardium, and new therapies regarding anticoagulation and vascular health. Current data regarding the worldwide epidemiology will be highlighted, as well as psychosocial issues, guidelines and nursing practice .

Since the historic first International Kawasaki Disease Symposium in 1984, the international symposium has been held every 3 years in Japan, the United States, or Taiwan, drawing attendees from all continents.

Who Should Attend -  The audience will consist of pediatric and adult cardiologists, pediatricians and pediatric subspecialists in immunology, infectious disease, and rheumatology;  cardiovascular surgeons; pathologists; basic scientists in genetics, molecular biology, microbiology, and cardiovascular pathophysiology; public health officials from county and state agencies and the Center for Disease Control and Prevention; epidemiologists; and nurses working in pediatric cardiology and public health who have an interest in Kawasaki disease.

LEARNING OBJECTIVES

Summarize prevailing hypotheses regarding KD etiology, and discuss emerging research supporting or contradicting these hypotheses.

Summarize current findings regarding diagnostic and prognostic biomarkers for KD, and their potential significance to clinical practice.

Summarize the most recent research and clinical findings regarding genetic susceptibility to KD and to KD coronary artery disease.

Summarize the most recent research and clinical findings regarding IVIG mechanism of action and the efficacy of additional or alternative therapies

Review evidence regarding the two distinct arterial processes that can lead to myocardial ischemia or infarction.

Review available imaging modalities for their ability to assess for presence of thrombosis and luminal myofibroblastic proliferation.

Summarize technical principles and current evidence supporting use of various imaging modalities in determining KD prognosis and optimal long-term follow-up.

Review evidence regarding the efficacy, safety, and long-term expected outcomes of revascularization options for KD patients.

Review current understanding, recent findings, and unresolved issues regarding optimization of thromboprophylaxis in KD patients.

Cardiologist, Cardiothoracic Surgeon, Epidemiologist, Microbiologist, Molecular Biologist, Pathologist, Patient, Pediatrician, Public Health Expert, Public Health Worker, Surgeon
7th Clinical Trials on Alzheimer’s Disease
United States
Pennsylvania
11/20/2014

7th Clinical Trials on Alzheimer’s Disease

November 20-22, 2014 Philadelphia, Pennsylvania

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, predict progression, and assess the effectiveness of new treatments.

The future of clinical trials may lie in the development of combination therapies of two or more drugs. CTAD 2014 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.
 

Neurologist, Physician Researcher
Antibiotic Alternatives for the New Millennium
United Kingdom
11/05/2014

Antibiotic Alternatives for the New Millennium

Wednesday, 05 November 2014 09:00-Friday, 07 November 2014 17:00 London, United Kingdom

The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new,clinically useful antibiotics, has refocused attention on finding alternatives to antibiotic treatments. This event will discuss the potential utility of phages, probiotics, antimicrobial peptides, herbal medicines and immune modulation for treating human and animal disease.

Who Should Attend

From researchers trying to find alternatives to therapies to pharmacists delivering treatments: any one with an interest in antibiotic alternatives would find this event of value.

Clinical Pharmacist, Pharmacist, Pharmacologist, Physician, Physician Researcher, Veterinary Scientist
16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014)
Czech Rep.
10/29/2014

16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014)

29 October – 1 November, 2014 Prague, Czech Republic

The 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID 2014), being held in the enchanting city of Prague, Czech Republic, offers unparalleled access to the latest research and analysis in the field. Meeting participants will gain valuable insights into innovative perspectives in both basic and clinical research. The scientific programme will draw together experts from around the world to discuss breakthroughs in diagnostic immunology, genetics and immunobiology of human diseases, advances in clinical practice, novel therapeutic approaches to tolerance induction and new insights into stem-cell and cellular therapies.

An ideal forum to share knowledge, connect with professional colleagues and grow your professional network, ESID 2014 is being held 29 October – 1 November, 2014.

Immunologist, Physician, Physician Researcher